ArticleJournal of managed care & specialty pharmacy2018

Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.

Rohit Mistry et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.